Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03193801 · ClinicalTrials.gov registry record · NA
PARTNER 3 Trial - Mitral Valve in Valve
A NA study of Heart Failure and Mitral Valve Insufficiency, sponsored by Edwards Lifesciences.
- Active
- Registry status
- NA
- Development phase
- 53
- Enrollment target
- 12
- Study locations
NCT03193801: Active NA study of Heart Failure and Mitral Valve Insufficiency, sponsored by Edwards Lifesciences.
NCT03193801 is a NA study of Heart Failure and Mitral Valve Insufficiency that is active but no longer recruiting, run by Edwards Lifesciences. The registered enrollment target is 53 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03193801, a NA study of Heart Failure and Mitral Valve Insufficiency, is active but no longer recruiting, sponsored by Edwards Lifesciences.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
- 12
- Study locations
Study Summary
To assess the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with a failing mitral bioprosthetic valve.
Primary Outcome
Non-hierarchical composite endpoint of all-cause mortality and stroke at 1-year post-procedure
Conditions Studied
Interventions
- DEVICE Edwards SAPIEN 3 transcatheter valve, Model 9600TFX
Study Locations (12)
Illinois
- Northwestern University - Chicago
- Northshore University Health System Research Institution - Evanston
São Paulo
- Instituto do Coração da Universidade de São Paulo - Cerqueira César
- Instituto Dante Pazzanese de Cardiologia - Vila Mariana
Georgia
- Emory University - Atlanta
Massachusetts
- Brigham and Women's Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Missouri
- Barnes-Jewish Hospital/ Washington University - St Louis
New York
- NYU Lagone Medical Center - New York
Oregon
- Providence Heart & Vascular Institution - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2031-08 |
| Phase | NA |
What the registry record for NCT03193801 still lists
NCT03193801 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Edwards SAPIEN 3 transcatheter valve, Model 9600TFX is the first listed.
NCT03193801 lists 12 locations in 10 states (Illinois, São Paulo, Georgia).
Frequently Asked Questions
What is clinical trial NCT03193801 about?
NCT03193801 is a clinical study titled "PARTNER 3 Trial - Mitral Valve in Valve". To assess the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with a failing mitral bioprosthetic valve.
What is the current status of trial NCT03193801?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 53 participants. The study started on 2018-02-01. Estimated completion is 2031-08.
What conditions does trial NCT03193801 study?
This clinical trial studies the following conditions: Heart Failure, Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Disease.
What interventions are being tested in trial NCT03193801?
The interventions under investigation include: Edwards SAPIEN 3 transcatheter valve, Model 9600TFX (DEVICE).
Who is sponsoring clinical trial NCT03193801?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03193801 being conducted?
This trial has 12 study locations across Georgia, Illinois, Massachusetts, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03193801's enrollment target sits among peer trials
53 277th of 397 higher than 119 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI